- Home
- EPIX vs ACRV Comparison
EPIX vs ACRV Comparison
Compare EPIX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- ACRV
- Stock Information
- Founded
- EPIX 2009
- ACRV 2018
- Country
- EPIX Canada
- ACRV United States
- Employees
- EPIX N/A
- ACRV N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- EPIX Health Care
- ACRV Health Care
- Exchange
- EPIX Nasdaq
- ACRV Nasdaq
- Market Cap
- EPIX 65.3M
- ACRV 59.9M
- IPO Year
- EPIX N/A
- ACRV 2022
- Fundamental
- Price
- EPIX $1.72
- ACRV $1.16
- Analyst Decision
- EPIX Hold
- ACRV Strong Buy
- Analyst Count
- EPIX 3
- ACRV 5
- Target Price
- EPIX $2.00
- ACRV $19.75
- AVG Volume (30 Days)
- EPIX 280.5K
- ACRV 1.3M
- Earning Date
- EPIX 05-08-2025
- ACRV 05-20-2025
- Dividend Yield
- EPIX N/A
- ACRV N/A
- EPS Growth
- EPIX N/A
- ACRV N/A
- EPS
- EPIX N/A
- ACRV N/A
- Revenue
- EPIX N/A
- ACRV N/A
- Revenue This Year
- EPIX N/A
- ACRV N/A
- Revenue Next Year
- EPIX N/A
- ACRV N/A
- P/E Ratio
- EPIX N/A
- ACRV N/A
- Revenue Growth
- EPIX N/A
- ACRV N/A
- 52 Week Low
- EPIX $1.40
- ACRV $1.30
- 52 Week High
- EPIX $7.88
- ACRV $10.29
- Technical
- Relative Strength Index (RSI)
- EPIX 52.43
- ACRV 28.93
- Support Level
- EPIX $1.67
- ACRV $1.32
- Resistance Level
- EPIX $1.79
- ACRV $1.50
- Average True Range (ATR)
- EPIX 0.08
- ACRV 0.17
- MACD
- EPIX -0.01
- ACRV 0.06
- Stochastic Oscillator
- EPIX 21.28
- ACRV 1.55
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.